Drug Trial Radar · NCT07032077
A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 9, 2025
Primary completion
Jun 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety and tolerability of HRS-7058 combined with antitumor drugs in subjects with solid tumors, and to determine the recommended dosage for Phase II. Evaluate the objective response rate of HRS-7058 in combination with anti-tumor drugs in subjects with solid tumors.
Conditions
- Solid Tumors
Interventions
HRS-7058Drug
HRS-7058 combined with antitumor drugs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of dose-limiting toxicities (DLT).Time frame: About 28 days.
- The incidence and severity of adverse events (AEs).Time frame: About 28 days.
- Recommended Phase 2 Dose (RP2D) of HRS-7058 in combination with antitumor drugs in subjects with solid tumors.Time frame: From the first dose to the last visit, about 12 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.